Neoadjuvant/preoperative gemcitabine for patients with localized pancreatic cancer: a meta-analysis of prospective studies - PubMed (original) (raw)
Review
. 2012 May;19(5):1644-62.
doi: 10.1245/s10434-011-2110-8. Epub 2011 Oct 20.
Affiliations
- PMID: 22012027
- DOI: 10.1245/s10434-011-2110-8
Review
Neoadjuvant/preoperative gemcitabine for patients with localized pancreatic cancer: a meta-analysis of prospective studies
Angelo Andriulli et al. Ann Surg Oncol. 2012 May.
Abstract
Background: Long-term prognosis for localized pancreatic cancer remains poor. We sought to assess the benefit of neoadjuvant/preoperative chemotherapy with or without radiotherapy.
Methods: Prospective studies where gemcitabine with or without radiotherapy was provided before surgery in patients with initially resectable or unresectable disease were reviewed by meta-analysis. Primary outcome was survival, and secondary outcomes were tumor response after therapy, toxicity, surgical exploration, and resection rates.
Results: Twenty independent studies with 707 participants were included, 366 with resectable lesions and 341 with unresectable lesions. Seven studies were phase I/II trials, 10 phase II, and 3 prospective cohort studies. Estimated 1- and 2-year survival probabilities after resection were 91.7% (95% confidence interval [CI] 75-100) and 67.2% (95% CI 38-87) for initially resectable patients, and 86.3% (95% CI 78-100) and 54.2% (95% CI 25-100) for initially unresectable patients. The complete/partial response rate was 12% (95% CI 4-23) and 27% (95% CI 18-38) in resectable and unresectable lesions, respectively. The rate of treatment-related grade 3-4 toxicity was 31% (95% CI 21-42). Of resectable patients evaluable after restaging, 91% (95% CI 83-97) underwent surgery, and 82% (95% CI 65-95) of explored patients underwent resection. R0 resections amounted to 89% (95% CI 83-94). Of unresectable patients evaluable after restaging, 39% (95% CI 28-50) underwent surgery, and 68% (95% CI 53-82) of explored patients were resected, with 60% (95% CI 50-71) R0 resections.
Conclusions: Current analysis provides marginal support to the assumed benefits of neoadjuvant therapies for patients with resectable cancer, and indicates a potential advantage only for a minority of those with unresectable lesions.
Similar articles
- NeoGemTax: gemcitabine and docetaxel as neoadjuvant treatment for locally advanced nonmetastasized pancreatic cancer.
Sahora K, Kuehrer I, Schindl M, Koelblinger C, Goetzinger P, Gnant M. Sahora K, et al. World J Surg. 2011 Jul;35(7):1580-9. doi: 10.1007/s00268-011-1113-8. World J Surg. 2011. PMID: 21523499 Clinical Trial. - Outcomes after neoadjuvant treatment with gemcitabine and erlotinib followed by gemcitabine-erlotinib and radiotherapy for resectable pancreatic cancer (GEMCAD 10-03 trial).
Maurel J, Sánchez-Cabús S, Laquente B, Gaba L, Visa L, Fabregat J, Povés I, Roselló S, Díaz-Beveridge R, Martín-Richard M, Rodriguez J, Sabater L, Conill C, Cambray M, Reig A, Ayuso JR, Valls C, Ferrández A, Bombí JA, Ginés A, García-Albéniz X, Fernández-Cruz L. Maurel J, et al. Cancer Chemother Pharmacol. 2018 Dec;82(6):935-943. doi: 10.1007/s00280-018-3682-9. Epub 2018 Sep 17. Cancer Chemother Pharmacol. 2018. PMID: 30225601 Clinical Trial. - Prospective phase II trial of neoadjuvant chemotherapy with gemcitabine and cisplatin for resectable adenocarcinoma of the pancreatic head.
Heinrich S, Pestalozzi BC, Schäfer M, Weber A, Bauerfeind P, Knuth A, Clavien PA. Heinrich S, et al. J Clin Oncol. 2008 May 20;26(15):2526-31. doi: 10.1200/JCO.2007.15.5556. J Clin Oncol. 2008. PMID: 18487569 Clinical Trial. - Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages.
Gillen S, Schuster T, Meyer Zum Büschenfelde C, Friess H, Kleeff J. Gillen S, et al. PLoS Med. 2010 Apr 20;7(4):e1000267. doi: 10.1371/journal.pmed.1000267. PLoS Med. 2010. PMID: 20422030 Free PMC article. Review. - Neoadjuvant Treatment for Borderline Resectable Pancreatic Ductal Adenocarcinoma.
Kaufmann B, Hartmann D, D'Haese JG, Stupakov P, Radenkovic D, Gloor B, Friess H. Kaufmann B, et al. Dig Surg. 2019;36(6):455-461. doi: 10.1159/000493466. Epub 2018 Nov 8. Dig Surg. 2019. PMID: 30408790 Review.
Cited by
- Pancreatic cancer: from state-of-the-art treatments to promising novel therapies.
Garrido-Laguna I, Hidalgo M. Garrido-Laguna I, et al. Nat Rev Clin Oncol. 2015 Jun;12(6):319-34. doi: 10.1038/nrclinonc.2015.53. Epub 2015 Mar 31. Nat Rev Clin Oncol. 2015. PMID: 25824606 Review. - Low concentrations of metformin selectively inhibit CD133⁺ cell proliferation in pancreatic cancer and have anticancer action.
Gou S, Cui P, Li X, Shi P, Liu T, Wang C. Gou S, et al. PLoS One. 2013 May 8;8(5):e63969. doi: 10.1371/journal.pone.0063969. Print 2013. PLoS One. 2013. PMID: 23667692 Free PMC article. - A prognostic Bayesian network that makes personalized predictions of poor prognostic outcome post resection of pancreatic ductal adenocarcinoma.
Bradley A, Van der Meer R, McKay CJ. Bradley A, et al. PLoS One. 2019 Sep 9;14(9):e0222270. doi: 10.1371/journal.pone.0222270. eCollection 2019. PLoS One. 2019. PMID: 31498836 Free PMC article. - An update on treatment options for pancreatic adenocarcinoma.
Lambert A, Schwarz L, Borbath I, Henry A, Van Laethem JL, Malka D, Ducreux M, Conroy T. Lambert A, et al. Ther Adv Med Oncol. 2019 Sep 25;11:1758835919875568. doi: 10.1177/1758835919875568. eCollection 2019. Ther Adv Med Oncol. 2019. PMID: 31598142 Free PMC article. Review. - Upfront Surgery versus Neoadjuvant Therapy for Resectable Pancreatic Cancer: Systematic Review and Bayesian Network Meta-analysis.
Bradley A, Van Der Meer R. Bradley A, et al. Sci Rep. 2019 Mar 13;9(1):4354. doi: 10.1038/s41598-019-40951-6. Sci Rep. 2019. PMID: 30867522 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical